FDA has approved Adolor Corp. and GlaxoSmithKline PLC’s bowel drug Entereg to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery. Entereg is the first and only product that has demonstrated the ability to address this serious condition, which has negative consequences for patients, and imposes considerable expense on the healthcare system. Entereg will be available for short-term use in hospitals registered under the Entereg Access Support and Education Program. The program is designed to monitor use and prevent long-term outpatient use.